Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment

Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia

(2017) Elliott F Winton et al.   Future Oncology

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis

(2016) Vikas Gupta et al.   HAEMATOLOGICA

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis

(2016) Vikas Gupta et al.   HAEMATOLOGICA

Inhibitor-based affinity probes for the investigation of JAK signaling pathways

(2015) Michael Höfener et al.   PROTEOMICS

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

(2013) A Pardanani et al.   LEUKEMIA

mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms

(2013) Costanza Bogani et al.   PLoS One

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

(2010) J. W. Tyner et al.   BLOOD

Molecular aspects of myeloproliferative neoplasms

(2010) François Delhommeau et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)

(2009) Christopher J. Burns et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

(2009) A Pardanani et al.   LEUKEMIA